Katena adds ophthalmic products used across cataract, glaucoma and corneal surgeries, including surgical instruments, single-use devices and specialty biologics that have been sold in more than 110 countries to more than 5,000 customers, including hospitals, ambulatory surgery centers and distributors. Katena has more than 200 employees across North America and Europe. The transaction represents Corza's first add-on acquisition since its formation in January 2021 with the transformational merger of Surgical Specialties and TachoSil, a carve-out from Takeda Pharmaceutical. Corza's current offerings are almost exclusively consumable and are used as single-use suture s or disposable hemostats in many applications so Katena adds a re-usable revenue stream along with cross-selling opportunities for common vendors and customers. Terms not announced.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Medical Devices, Ophthalmic Instruments, Surgical Instruments